SCHEMBL23826577

SCHEMBL23826577

C[C@H](N)C1(F)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
DPP4 P27487 2/20 0.41
HPGD P15428 1/20 0.40
EPHX2 P34913 1/20 0.40
ATM Q13315 2/20 0.39
HTT P42858 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23826580 1.00 USP2 (0.46) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL23826538 0.85 USP2 (0.44) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL23826536 0.85 USP2 (0.44) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL23826255 0.84 USP2 (0.43) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL23826252 0.84 USP2 (0.43) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL6228410 0.83 USP2 (0.55) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL23826809 0.83 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL22196335 0.83 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL18423086 0.83 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15DPP4
SCHEMBL15657911 0.83 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113302184-B 1,3, 4-Oxadiazolinone compounds and medicaments 日本新药株式会社 2024-11-22 CN disclosed
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2022-01-27 US disclosed
EP-3882239-A1 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2021-09-22 EP disclosed
CN-113302184-A 1,3, 4-oxadiazolinone compounds and drugs 日本新药株式会社 2021-08-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL PIM1, PIM3, PIM2 USP2 4793/4885SMN1; SMN2 4744/4885TSHR 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.